NCT00169988View on ClinicalTrials.gov

Antidepressant and Antipsychotic to Treat Attenuated Positive and Negative Symptoms

NACompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

March 31, 2004

Study Completion Date

April 30, 2007

Conditions
Prodromal SchizophreniaPsychotic Disorders
Interventions
DRUG

risperidone

DRUG

sertraline-primary

Trial Locations (1)

11004

RAP Program, Dept. of Psychiatry Research, The Zucker Hillside Hospital, Glen Oaks

Sponsors

Lead Sponsor

Northwell Health

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Stanley Medical Research Institute

OTHER

collaborator

Janssen Pharmaceutica N.V., Belgium

INDUSTRY

collaborator

Pfizer

INDUSTRY

lead

Northwell Health

OTHER

NCT00169988 - Antidepressant and Antipsychotic to Treat Attenuated Positive and Negative Symptoms | Biotech Hunter | Biotech Hunter